Abstract. Recently published actively controlled outcome trials in hypertension compared conventional therapy (diuretics and ␤-blockers) with newer antihypertensive drug classes, including angiotensin-converting enzyme inhibitors, calcium channel blockers, ␣-blockers, and angiotensin II antagonists. In a quantitative overview of nine trials including 62,605 randomized patients, it was found that conventional therapy and newer drug classes had similar long-term efficacy in preventing cardiovascular complications of hypertension. BP lowering largely accounted for most, if not all, of the observed benefits in cardiovascular outcome. These findings emphasize the desirability of lowering BP as much as possible to maximize the reduction in cardiovascular complications. Furthermore, several clinical trials have been specifically designed to highlight specific mechanisms of action of the newer drugs by measuring intermediate end points, such as carotid intima-media thickening or renal dysfunction, or by studying subgroups of patients with specific disorders, such as diabetes mellitus. In these trials, calcium channel blockers were more effective than conventional therapy in preventing carotid intimamedia thickening and mild renal dysfunction, whereas use of calcium channel blockers or angiotensin-converting enzyme inhibitors was associated with a lower incidence of diabetes mellitus in some studies. However, whether or not these specific effects of the newer drugs on intermediary and/or metabolic end points in the long run also lead to fewer cardiovascular complications remains to be proved.
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The lifetime risk of hypertension is approximately 20%. By lowering BP, antihypertensive drugs diminish cardiovascular risk in hypertensive patients (1, 2) . Among the currently recommended antihypertensive agents, diuretics and ␤-blockers are considered as conventional therapy, whereas angiotensinconverting enzyme (ACE) inhibitors, calcium channel blockers, ␣-blockers, and angiotensin II type 1 receptor antagonists are viewed as newer drug classes (3, 4) . There is clear evidence that diuretics and ␤-blockers may not only lower BP but also prevent cardiovascular complications of hypertension, such as stroke and myocardial infarction (1) . To provide similar evidence for the newer drug classes, 11 actively controlled outcome trials have been reported before the end of 2001 in which conventional therapy was used as the reference treatment (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Three meta-analyses have been published on the basis of these trials (16 -18) .
The present review is mainly based on our previous metaanalysis (18) of nine actively controlled trials in hypertension, which specifically compared newer drug classes with conventional therapy. In addition, we also summarize the recently published LIFE (Losartan Intervention For Endpoint reduction in hypertension) study (19, 20) . Among the individual trials with information on one or more of the fatal outcomes (7-12,14,15), there were no differences in cause-specific mortality between the newer and older drugs with the exception of the 3.22 (95% CI, 1.12 to 11.2; P ϭ 0.03) increase in fatal myocardial infarction on treatment with nifedipine GITS (gastro-intestinal transfer system) in the INSIGHT trial (11) . For none of the pooled results, Zelen's test indicated significant heterogeneity ( Table 2 ). The new drugs were equally effective as the old ones in preventing cardiovascular mortality or deaths from stroke or myocardial infarction with or without sudden death (18) .
Overall Cardiovascular Prevention
With regard to fatal combined with nonfatal outcomes, there was significant heterogeneity among the trials, which was largely driven by the higher risk of cardiovascular complications (Table 3) , stroke, and congestive heart failure on treat- ment with doxazosin compared with chlorthalidone in the ALLHAT trial (13, 18) . After exclusion of ALLHAT (13), there was still slight heterogeneity in the overall risk of cardiovascular complications on treatment with ACE inhibitors compared with conventional therapy (Table 3 ; P Յ 0.03). This was due to the higher risk of stroke in the CAPPP patients randomized to captopril (18) . The odds ratio was 1.25 (95% CI, 1.01 to 1.55; P ϭ 0.04) (8) . Among the individual trials, NORDIL patients allocated diltiazem had a lower risk of stroke than their counterparts randomized to the older drug classes Table 1 with the exception of ALLHAT, because cardiovascular mortality was unavailable from the published report (13) .
c Negative values indicate better outcome on the newer drugs. d P value greater than 0.05 indicates that the hypothesis of heterogeneity across the trials was rejected. (diuretics and/or ␤-blockers). The odds ratio was 0.80 (95% CI, 0.65 to 0.99; P ϭ 0.04) (12), but did not lead to significant heterogeneity among the trials involving calcium channel blockers. After exclusion of ALLHAT (13), there were no differences in overall cardiovascular risk between the patients randomized to diuretics or ␤-blockers compared with those allocated initial treatment with calcium channel blockers or ACE inhibitors (Table 3 ). However, in the patients randomized to calcium channel blockers compared with those in whom treatment had been started with older drugs, there was a greater reduction in the risk of stroke (13.5%; 95% CI, 1.3 to 24.2%; P ϭ 0.03) and a smaller decrease in the risk of myocardial infarction (19.2%; 95% CI, 3.5 to 37.3%; P ϭ 0.01). In contrast, ACE inhibitors conferred benefits in the prevention of stroke and myocardial infarction that were similar to those of the old drug classes (18) .
Among the trials leading to significant heterogeneity (8, 13) and those with significant differences between the treatment groups in the overall risk of cardiovascular events (13) or cause-specific cardiovascular complications (8, 12, 13) , all three reported differences in the achieved systolic pressure of 2 mmHg or more (Table 1) . Therefore, in a further analysis we investigated the relationship between the odds ratios expressing benefit and the achieved differences in systolic BP between the treatment groups. In this meta-regression analysis, we included nine actively controlled trials (Table 1) (7-15) and 21 previous drug trials in hypertension (for acronyms and original publications, see reference 18) or in patients at high cardiovascular (21) (22) (23) , cerebrovascular (24, 25) , or renal risk (26) . The meta-regression line between the odds of an event and the differences in systolic pressure between the study groups was linear for cardiovascular mortality (18) and curvilinear for all cardiovascular events (Figure 1 ), fatal and nonfatal stroke (18), Figure 1 . Relationships between the odds ratios for all cardiovascular events and the corresponding differences in systolic BP. Odds ratios were calculated for experimental versus reference treatment and BP differences by subtracting the achieved level in the experimental group from that in the reference group. The regression lines were plotted with 95% confidence interval (CI) and were weighted for the inverse of the variance of individual odds ratios. Adapted with permission from Staessen et al. (18) . and fatal and nonfatal myocardial infarction, including sudden death (18) . The differences between the observed odds ratios and those predicted by the meta-regression lines (Figure 1 ) did not reach statistical significance except for the NORDIL (12) and PROGRESS (Perindopril Protection Against Recurrent Stroke Study) (25) trials. In NORDIL, the risk of stroke was lower on diltiazem than on the older drug classes despite a 3.1-mmHg higher systolic pressure on the calcium channel blocker. In the perindopril-only subgroup of the PROGRESS trial (25) , systolic pressure was reduced by 5 mmHg, but monotherapy with the ACE inhibitor did not affect the risk of all cardiovascular events (Figure 2 ) or stroke recurrence (Figure 3) 
Other Outcomes
The benefits of conventional therapy and the newer antihypertensive drug classes in preventing cardiovascular complications are similar and to a large extent depend on BP reduction (18) . However, antihypertensive drugs have different mechanisms of action. Several clinical trials have been specifically designed to highlight these differences by measuring intermediate end points, such as carotid intima-media thickening (7,27-29) or mild renal dysfunction (9,11), or by studying subgroups of patients with specific disorders, such as diabetes mellitus (8, 20) .
Renal Dysfunction
In the INSIGHT trial, the patients started on long-acting nifedipine had significantly (P Ͻ 0.0001) lower incidence rates of mildly impaired renal function and hyperuricemia than those assigned conventional therapy with co-amilozide (11) . The numbers of incident cases of renal failure were 8 and 13 in patients treated with nifedipine and co-amilozide, respectively (11) . In the NICS trial in 414 elderly hypertensive Japanese subjects (9), serum uric acid at the end of follow-up was 27.3 mol/L lower in subjects treated with sustained-release nicardipine than in those on trichlormethiazide (P Ͻ 0.0001). Blood urea nitrogen also tended to be lower in nicardipine-treated subjects (P ϭ 0.07).
Intima-Media Thickening
Intima-media thickening was the primary outcome measure in the MIDAS (7) and VHAS (27) trials and in a substudy to the INSIGHT trial (28) . In the MIDAS trial, mean intimamedia thickening over 3 yr of follow-up was smaller in patients on the dihydropyridine calcium channel blocker isradipine than in those randomized to hydrochlorothiazide (7). In the VHAS trial, although the results of intima-media thickness favored verapamil, the difference between this non-dihydropyridine calcium channel blocker verapamil and chlorthalidone did not reach significance (27) . Figure 2 . Observed and predicted odds ratios for all cardiovascular events. Observed odds ratios were reported in the published articles. Predicted odds ratios were derived from the regression model. Odds ratios were represented by the point estimate and 95% CI.
In a substudy to the INSIGHT trial (11), common carotid intima-media thickness progression was compared between long-acting nifedipine and co-amilozide in 439 enrolled patients (28) . With similar BP reduction, the progression rate of intima-media thickness (slope of intima-media thickness regression over time) in the nifedipine group compared with co-amilozide tended to be slower in 324 patients who were followed for at least 1 yr (P ϭ 0.09) and was significantly smaller in the 242 patients who had completed follow-up (Ϫ0.7 versus ϩ7.7 m/yr; P ϭ 0.002). In line with these results of carotid intima-media thickness (28) , another IN-SIGHT project that involved annual double-helix computerized tomography of the heart, showed that, compared with diuretics, long-acting nifedipine decreased the progression of coronary artery calcification during 3 yr of follow-up in 201 hypertensive patients (29) .
The carotid arterial results of the three trials comparing a calcium channel blocker with diuretics (7,27,28) suggest that the anti-atherosclerotic effect of calcium channel blockade, which have been shown in previous placebo-controlled trials (30, 31) , might be independent of BP reduction.
Diabetes Mellitus
Several recent trials reported the incidence of diabetes mellitus in patients on treatment with different antihypertensive drugs (8 -12,20) . The INSIGHT trial demonstrated that, compared with co-amilozide, calcium channel blockade (nifedipine) significantly reduced the incidence of diabetes mellitus by 30% (P ϭ 0.01) (11) . A similar tendency was also observed in NORDIL (Ϫ13%; P ϭ 0.14) (12) and NICS (4 versus 0 cases; P ϭ 0.12) (9), but not in the STOP2 study (P ϭ 0.83) (10) . The CAPPP trial found a 14% (P ϭ 0.04) reduction in diabetes mellitus in patients on captopril as compared with those on diuretics and ␤-blockers (8). However, the latter observation was not confirmed in the STOP2 trial (10) . The conflicting findings in the STOP2 trial may be due to the high crossover of study medications between the study groups to be compared (10) . More recently, the LIFE study found a 25% reduction in the incidence of diabetes mellitus in patients treated with losartan as compared with atenolol (20) . Because the old drugs do have metabolic adverse effects and all three classes of new drugs showed similar benefits in this regard, one may postulate that the difference in the risk of diabetes between old and new drugs classes may be due to an impairment of glucose metabolism on conventional therapy in particular diuretics.
The UKPDS trial (15) and subgroup analyses of other comparative trials (8, 12, 20, 32) focused on the cardiovascular outcome of hypertensive patients with diabetes mellitus. In STOP2 (32) and NORDIL (12), calcium channel blockers provided similar cardiovascular benefit as conventional therapy in the diabetic subgroup. The CAPPP trial showed in 572 diabetic patients that captopril was better than conventional therapy in preventing fatal and nonfatal myocardial infarction (8) . However, this finding was not confirmed by the STOP2 (32) and UKPDS (15) trials, which respectively included 488 and 758 diabetic patients.
In 1195 hypertensive diabetic patients with electrocardio- graphic left ventricular hypertrophy, the LIFE trial demonstrated that compared with atenolol losartan significantly reduced total mortality by 39% (20) . However, similar reductions were observed for cardiovascular (Ϫ38%) and noncardiovascular (Ϫ42%) mortality. Moreover, on randomized treatment, systolic pressure was 3 mmHg lower in the losartan group as compared with the patients randomized to atenolol (20) .
Conclusions
The actively controlled trials demonstrated that on average conventional therapy and the newer antihypertensive drugs have similar long-term efficacy and safety. Compared with the older drug classes, calcium channel blockers and converting enzyme inhibitors provided the same overall protection against cardiovascular complications. In the trials in hypertensive and/or high-risk patients, BP lowering largely accounted for most, if not all, of the observed benefits in cardiovascular outcome. These findings emphasize the desirability of lowering BP as much as possible to maximize the reduction in cardiovascular complications. Whether or not the specific effects of the newer drugs on intermediary or metabolic end points in the long-run also lead to fewer cardiovascular complications remains to be proved.
